| Dr Jennifer A Wright, PHD | |
|
911 Bypass Rd Bldg A, Pikeville, KY 41501-1689 | |
| (606) 430-2205 | |
| (606) 218-7507 |
| Full Name | Dr Jennifer A Wright |
|---|---|
| Gender | Female |
| Speciality | Clinical Psychologist |
| Experience | 14 Years |
| Location | 911 Bypass Rd Bldg A, Pikeville, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861607459 | NPI | - | NPPES |
| 7100353010 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 103T00000X | Psychologist | 1692 (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pikeville Medical Center Inc | 6709790157 | 314 |
News Archive
The U.S. Food and Drug Administration has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.
Neuroscience Therapy Corp. has unveiled its leading product: P-Stim Electro Stimulation Device.
UBM TechInsights today warned the consumer medical device industry that the smartphone juggernaut will impact revenues, design strategies, and intellectual property management for medical devices in the same way it has for many consumer products including cameras, GPS devices and personal media players.
A groundbreaking new wearable designed to be worn on the throat could be a game-changer in the field of stroke rehabilitation.
Unigene Laboratories, Inc. today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa's oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.
› Verified 7 days ago
| Entity Name | Pikeville Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528195864 PECOS PAC ID: 6709790157 Enrollment ID: O20040304001281 |
News Archive
The U.S. Food and Drug Administration has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.
Neuroscience Therapy Corp. has unveiled its leading product: P-Stim Electro Stimulation Device.
UBM TechInsights today warned the consumer medical device industry that the smartphone juggernaut will impact revenues, design strategies, and intellectual property management for medical devices in the same way it has for many consumer products including cameras, GPS devices and personal media players.
A groundbreaking new wearable designed to be worn on the throat could be a game-changer in the field of stroke rehabilitation.
Unigene Laboratories, Inc. today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa's oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer A Wright, PHD Po Box 432, Pikeville, KY 41502-0432 Ph: (606) 230-2205 | Dr Jennifer A Wright, PHD 911 Bypass Rd Bldg A, Pikeville, KY 41501-1689 Ph: (606) 430-2205 |
News Archive
The U.S. Food and Drug Administration has approved Risperdal (risperidone) for the treatment of schizophrenia in adolescents, ages 13 to 17, and for the short-term treatment of manic or mixed episodes of bipolar I disorder in children and adolescents ages 10 to 17.
Neuroscience Therapy Corp. has unveiled its leading product: P-Stim Electro Stimulation Device.
UBM TechInsights today warned the consumer medical device industry that the smartphone juggernaut will impact revenues, design strategies, and intellectual property management for medical devices in the same way it has for many consumer products including cameras, GPS devices and personal media players.
A groundbreaking new wearable designed to be worn on the throat could be a game-changer in the field of stroke rehabilitation.
Unigene Laboratories, Inc. today noted that Tarsa Therapeutics has completed patient enrollment in the Phase III ORACAL trial of Tarsa's oral calcitonin product for the treatment of postmenopausal osteoporosis. Unigene licensed the product to Tarsa and owns 26% of the company.
› Verified 7 days ago
Alfred Bradley Adkins, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 911 Bypass Rd, Pikeville, KY 41501 Phone: 606-218-3500 | |
Dr. Eric Robert Johnson, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 113 Robert Cir, Pikeville, KY 41501 Phone: 606-432-8635 | |
Catherine D. Huffman, PSY D Psychologist Medicare: Medicare Enrolled Practice Location: 238 Cassidy Blvd, Pikeville, KY 41501 Phone: 606-430-2230 Fax: 606-437-2526 | |
Dr. Brandon R Olive, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 338 Douglas Dr, Pikeville, KY 41501 Phone: 859-640-3870 | |
Mrs. Carman Ann Parker, DO Psychologist Medicare: Not Enrolled in Medicare Practice Location: 1098 S Mayo Trl, Suite 301, Pikeville, KY 41501 Phone: 606-437-2121 Fax: 606-433-1867 | |
Ms. Dorothy Holian, PSY.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 118 River Dr, Pikeville, KY 41501 Phone: 606-432-3143 Fax: 606-437-5412 |